FDA updated Safety Communication: Ondansetron (Zofran) 32-mg, single IV dose pulled due to potential for serious cardiac risks

Article

The 32-mg, single intravenous dose of the anti-nausea drug Zofran will no longer be marketed because of the potential for serious cardiac risk, according to an updated Safety Communication from FDA.

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Recent Videos
2 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.